SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results topped expectations and marked its first profit since its IPO, with rapid growth in its AI-compute business and plans for heavy infrastructure spending driving attention. Many traders welcomed the growth and outlook, while others questioned the valuation, spending and share-unlock risk; discussion of a possible Tesla merger added speculation, but no deal is assured.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary first-quarter update sharply raised its revenue and gross-margin outlook, citing stronger AI-platform demand, sparking a surge in shares. Traders largely welcomed the update as evidence of robust AI-server demand and anticipated short covering, while some questioned whether the gains would hold given the companys execution and credibility concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs earnings beat was overshadowed by softer fourth-quarter guidance, slowing revenue growth and a reduced advertising outlook, prompting a sharp selloff. Traders are debating whether the drop reflects worsening growth prospects or an overreaction to the outlook, with some pointing to continued profitability as a reason to buy the dip.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas rebound is drawing attention amid confirmed formation of special committees to explore a potential SpaceX merger, though Musk said a deal is uncertain and would require shareholder support. Traders are split between enthusiasm over possible synergies and skepticism about the terms and timing, while positioning around Teslas Q3 earnings adds volatility.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is being swept up in a sharp memory-chip and Korean-market selloff, with traders citing KOSPI weakness, foreign selling, and fears about Chinese competition and the durability of the AI-driven memory cycle. Bulls argue the decline is excessive given strong memory demand and low valuations, while bears see further downside risk from cyclical and oversupply concerns.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Q3 earnings expectations dominate, with traders debating whether results and guidance can support Bloom Energys premium valuation after a sharp pullback. Bulls point to fuel-cell demand from AI data centers, while skeptics cite valuation risk and broader weakness in AI-related stocks.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads sharp rally is driven mainly by its agreement to sell its prenatal testing business to Labcorp for $210 million in cash plus inventory value, which traders view as a major cash infusion and a shift toward oncology. Bulls see the deal as a balance-sheet and strategic positive, while skeptics argue that selling a revenue-generating unit leaves a smaller business with ongoing debt and execution concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDAs acceptance of REZZAYOs supplemental application for Priority Review is drawing attention, with traders focused on a possible expansion into invasive-fungal-disease prevention and the pending FDA decision. Optimism about that opportunity is tempered by concerns over DefenCath reimbursement and adoption, management execution, and the stocks muted response to positive developments.

Braze, Inc. operates a customer relationship management platform for mobile applications. Its application combines messaging, audience segmentation, analytics and user support in a single integrated solution. The firm offers push notifications, email, in-app messages, and news feed services. The company was founded by Mark Ghermezian, William Magnuson, and Jonathan Hyman on March 28, 2011 and is headquartered in New York, NY.

Braze Inc - Ordinary Shares - Class A

Braze Inc

Salesforces agreed cash acquisition of Braze at a substantial premium is driving the sharp share-price surge, with traders celebrating the buyout while weighing the remaining merger-arbitrage spread and the long wait for the deal to close. Analysts post-deal downgrades have also prompted discussion, though some view the transaction as a win for shareholders and a potential boost to software-sector deal activity.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in acute bipolar mania met its primary and secondary endpoints, prompting a burst of bullish interest. Traders are divided over whether the efficacy is strong enough to outweigh concerns about agitation and higher treatment discontinuations, with the initial rally fading amid profit-taking and short-selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows

Revvity, Inc. (NYSE: RVTY), announced that its Revvity Signals Software business is launching the Signals LabGistics solution, an AI-first, scientific workflow orchestration solution designed to connect and coordinate processes, workflows, and tasks from discovery to manufacturing. The Signals...

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings

DGX heads into Q3 earnings with expected revenue and EPS growth, fueled by strong clinical demand, advanced diagnostics and operational efficiencies.

Here's How Much $100 Invested In Revvity 15 Years Ago Would Be Worth Today

Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.91% on an annualized basis producing an average annual return of 15.11%. Currently, Revvity has a market capitalization of $17.36 billion.read more...

Thermo Fisher to Report Q3 Earnings: What's in the Cards?

TMO gears up for Q3 earnings, with revenue and EPS growth expected amid strong bioproduction demand, product innovations and clinical research strength.

Revvity to Present at Upcoming Investor Conferences

Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026 8:00 a.m. GMT Prahlad Singh, president and chief executive officer 9th Annual Evercore Healthcare Conference Wednesday, December...

Revvity to Host Investor Day

Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.Presentations from members of Revvitys senior management team will provide updates on the Companys key business initiatives, operational achievements and financial outlook.To...

Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?

Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Revvity to Hold Earnings Call on November 3, 2026

Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive...

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.

Revvity Inc.

Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’

Equity

Bearish Sentiment

Revvity, Inc. (RVTY) CEO Prahlad Singh acknowledged challenges to the company’s immunodiagnostics business in China, owing to changes in regulations, and warned of a pullback during the firm’s earnings call on Monday.The CEO stated that the company began experiencing challenges in its diagnostics business midway through the second quarter, due to a revised lab reimbursement policy tied to Diagnosis-Related Groups (DRGs), which affected the size of diagnostic panels ordered by physicians in the country.Healthcare providers are opting for fewer multiplex diagnostic products, the CEO said, while noting that this trend is likely to drive volume for single-plex tests.“For the remainder of the year, we are now expecting a fairly meaningful pullback in our immunodiagnostics business in China, which is incorporated into our updated outlook for the total company for the year,” Singh said. The immunodiagnostics business in China represents 6% of the company’s total revenue.Shares of the company slid 8% as of Monday afternoon, at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RVTY">RVTY</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1358/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_28_at_1_30_31_PM_png_4f6a008503.webp" alt="RVTY's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 28, 2025 | Source: Stocktwits" width="1358" height="124"><figcaption>RVTY's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the drop in stock on Monday is an overreaction, and that it is being overly punished for a change in Chinese regulation.<stembedurl>https://stocktwits.com/Spartan2008/message/622689408</stembedurl>Yet another opined that the change in regulation applies to all companies in the space and that the company has sufficient cash on hand.<stembedurl>https://stocktwits.com/YouOnlyLiveTwice/message/622719140</stembedurl>For the full year 2025, the company has raised its revenue guidance to $2.84 billion to $2.88 billion, reflecting recent changes in foreign currency exchange rates and assuming 2% to 4% organic growth.The company also updated its adjusted earnings per share guidance to a range of $4.85 to $4.95, down from its previous guidance of $4.90 to $5.For the second quarter, the company’s revenue came in at $720 million, marking a 4% growth and exceeding an analyst estimate of $711.33 million, according to data from Fiscal AI.Adjusted earnings per share for the quarter came in at $1.18, compared to $1.22 in the corresponding period of 2024, but above an expected $1.14.RVTY stock is down by 14% this year and by about 24% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cervomed-dementia-drug-slows-disease-progression-in-study/choeuj6R5xa">CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Revvity company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Healthcare providers are opting for fewer multiplex diagnostic products, the CEO said, while noting that this trend is likely to drive volume for single-plex tests.

iShares Core Growth Allocation ETF

American Century ETF Trust - Avantis U.S. Equity ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$RVTY has 3 green bricks and is extended. It is possible that it can go back to 2 green bricks if the price moves lower.

Renko Trading System

$RVTY (Revvity Inc.) 
 
System Status: EXECUTE LONG POSITION 
 
Technical Breakdown 
Macro Strength: Top-tier fundamental and technical alignment with an exceptional SCTR of 96.5, strong Weekly RSI at 76.58, and a clear green brick trend above a rising 20-EMA ($127.78). 
 
Pullback & Trigger: The 195-minute chart successfully completed a healthy 3-red brick pullback into the rising 20-EMA ($150.38) with StochRSI resetting below 0.20. It has now printed two confirmed green bricks, fully satisfying the system entry rule. 
 
Execution Checklist 
Action: Enter Long Position (RVTY) 
Entry Price: Current market structure ($154.53) 
 
Risk Management: Hard stop beneath the recent pullback swing low ($149.94).

$RVTY is still set up with 2 green bricks. 
 
XLV is the strongest Sector with all the health industries in uptrends. 
 
$SPY

Feed

News

Sentiment

Earnings

Fundamentals

Info

RVTY Revvity Inc.

Fundamentals

Latest RVTY News